On Thursday, Evolus received a positive adjustment to its Relative Strength (RS) Rating, from 67 to 75.
This exclusive rating from Investor's Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an 80 or higher RS Rating as they begin their biggest price moves. See if Evolus can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Evolus is building a cup with handle with a 14.92 entry. See if it can clear the breakout price in heavy volume.
Evolus posted 0% EPS growth in the latest quarterly report, while sales growth came in at 22%. Keep an eye out for the company's next round of numbers on or around Feb. 26.
The company holds the No. 14 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Jazz Pharmaceuticals and Novartis ADR are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
